Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.35 USD | -1.80% | -3.50% | +16.77% |
31/05 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
31/05 | Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.77% | 202.29Cr | |
-4.27% | 1.24TCr | |
-0.60% | 843.33Cr | |
+6.91% | 576.58Cr | |
-10.21% | 410.34Cr | |
-60.35% | 265.63Cr | |
+10.62% | 266.4Cr | |
-7.40% | 239.16Cr | |
-9.18% | 177.15Cr | |
-2.30% | 151.26Cr |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Earnings Flash (MYGN) MYRIAD GENETICS Reports Q3 EPS $-0.03, vs. Street Est of $-0.02